Compare Repligen Corporation Common Stock (RGEN) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs State Street PDR S&P Retail ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while State Street PDR S&P Retail ETF trades at $84.83 (market cap $374.32M). The key difference: Repligen Corporation Common Stock is far larger — about 29.8× State Street PDR S&P Retail ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| RGEN | XRT | |
|---|---|---|
Market Cap | $11.14B | $374.32M |
Volume | 1,259,263 | 3,523,512 |
Sector | Health | Broad Market / Factor |
52-Week High | $194.57 | $92.35 |
52-Week Low | $102.87 | $77.28 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XRT (SPDR S&P Retail ETF) trades at $84.33, showing minimal daily movement with a 0.21% gain. Technical indicators present a mixed picture with bearish moving averages but neutral overall signals. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with recent retail sales showing volatility. XRT has underperformed the broader market year-to-date, reflecting sector-specific challenges in the retail landscape.
The retail sector outlook remains cautious amid macroeconomic pressures, though potential trade resolution benefits and holiday sales projections offer some optimism. Key risks include consumer spending sensitivity to economic conditions and competitive pressures. Analyst sentiment leans neutral with expectations of continued relative underperformance versus broader market indices into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
